GLENWOOD, Ill., Dec. 14, 2015 /PRNewswire/ -- Landauer,
Inc. (NYSE: LDR), a recognized leader in personal and
environmental radiation measurement and monitoring, outsourced
medical physics services and high quality medical consumable
accessories, today reported financial results for its fiscal 2015
fourth quarter and full year ended September
30, 2015.
Fiscal 2015 Highlights
- Revenue of $151.3 million, a 2.4%
decrease compared to fiscal 2014
- Domestic Radiation Measurement services revenues grew 2.4%
year-over-year
- Medical Physics revenues grew 9.9% year-over-year
- Excluding the $5.3 million
unfavorable impact of foreign currency exchange rates, revenues
increased 1.0%
- Operating income of $23.7
million, compared to an operating loss of $40.0 million in the prior year
- Adjusted operating income decreased $0.7
million compared to fiscal 2014
- Excluding the $1.3 million
unfavorable net impact of foreign currency exchange rates, adjusted
operating income increased $0.6
million
- Net income of $14.5 million,
compared to a net loss of $25.2
million in the prior year
- Adjusted net income of $17.0
million increased $0.7 million
compared to fiscal 2014
- Adjusted EBITDA of $40.6 million,
a decrease of 8.7% year-over-year
- Successfully executed divestiture of Radon business
- Company issues Fiscal 2016 guidance
Mike Kaminski, President and
Chief Executive Officer of Landauer stated, "We are pleased with
our fiscal 2015 financial results, which were in line with our
expectations and reflect the strong demand for our solutions. As we
enter 2016, we believe we have the right plan in place to leverage
Landauer's unique market position and execute on significant growth
opportunities in our core product platform. We expect the growth in
imaging physics to continue in fiscal 2016, and we are anticipating
strong demand for our new informatics solutions."
Fourth Quarter Financial Overview
Revenues for the fourth fiscal quarter of 2015 were $40.2 million, a 4.3% decrease compared to
revenues of $42.0 million for the
fourth quarter of fiscal 2014. Radiation Measurement revenues for
the quarter were $28.1 million, a
10.5% decrease compared to $31.4
million for the fourth fiscal quarter of 2014. The decrease
in revenues was driven by a $2.3
million decrease in military sales and a $1.7 million sale of custom equipment to an
international customer in the fourth fiscal quarter of 2014. In
addition, the unfavorable impact of changes in foreign currency
exchange rates was $1.6 million.
Partially offsetting the decrease in revenues were higher domestic
service revenues of $0.6 million and
an increase in product sales in France. Medical Physics revenues increased
$1.2 million, due to greater demand
for commissioning and imaging services. Medical Products revenues
increased $0.2 million.
Operating income for the quarter was $6.8
million, an 8.1% decrease compared to operating income of
$7.4 million for the fourth quarter
of fiscal 2014. The decrease in operating income was driven by
lower Radiation Measurement product sales and the negative impact
of foreign currency. On a sequential quarter basis, adjusted
operating income margin increased to 20.9% in the fourth fiscal
quarter of 2015 from 14.4% in the third fiscal quarter of 2015.
Fiscal Year Ended September 30,
2015 Financial Overview
Revenues for fiscal 2015 were $151.3
million, a 2.4% decrease compared to revenues of
$155.1 million for fiscal 2014.
Revenues in the Radiation Measurement segment decreased
$7.6 million due to the unfavorable
foreign currency impact of $5.3
million and a decrease in product sales to the military of
$2.2 million. Revenues in the Medical
Physics segment increased $3.2
million, primarily driven by increased imaging services
revenues of $2.2 million. Revenues in
the Medical Products segment increased $0.6
million primarily due to the full-period impact of a modest
acquisition in December 2013.
Operating income for fiscal 2015 was $23.7 million, compared to an operating loss of
$40.0 million for fiscal 2014. The
increase in operating income was due to the goodwill and other
intangible assets impairment charge recorded in the prior year that
was not present in fiscal 2015. Adjusted operating income margins
were 16.7% in fiscal 2015 compared to 16.8% in fiscal 2014.
Fiscal 2016 Outlook
The Company anticipates aggregate revenues for fiscal 2016 to be
in the range of $150 million to
$157 million.
Fiscal 2016 guidance reflects an expected year-over-year
reduction in sales due to unfavorable foreign currency rates of
$2.9 million and excludes revenues
from our Radon business, which was divested on September 30, 2015. Fiscal 2015 revenues,
excluding approximately $4.7 million
of revenues from our Radon business, were $146.6 million.
The Company anticipates adjusted net income for fiscal 2016 in
the range of $15 million to
$18 million. Fiscal 2015 adjusted net
income, excluding approximately $0.8
million from our Radon business, was $16.2 million.
Use of Non-GAAP Financial Measures
Adjusted EBITDA is presented here not as an alternative to net
income, but rather as a measure of the Company's operating
performance and is not intended to be a presentation in accordance
with GAAP. Since EBITDA (generally, net income plus interest
expenses, taxes, depreciation and amortization) is not calculated
identically by all companies, this presentation may not be
comparable to EBITDA or Adjusted EBITDA presentations disclosed by
other companies. Adjusted EBITDA represents net income with
adjustments for net financing costs, depreciation and amortization,
provision for income taxes, stock compensation expense, goodwill
and other intangible assets impairments, and acquisition,
reorganization and nonrecurring costs. Management believes that
Adjusted EBITDA is useful in evaluating the Company's operating
performance compared to that of other companies in its industry
because the calculation of Adjusted EBITDA generally eliminates the
effects of certain non-cash and other items that may vary for
different companies for reasons unrelated to overall operating
performance.
In addition, the Company's management used Adjusted Operating
Income and Adjusted Net Income as measures of earnings to eliminate
the effects of certain non-cash and nonrecurring items of the
Company. Adjusted Operating Income represents operating income with
adjustments for goodwill and other intangible assets impairments
and acquisition, reorganization and nonrecurring costs. Adjusted
Net Income represents net income with tax-effected adjustments for
stock compensation expense, goodwill and other intangible assets
impairments and acquisition, reorganization and nonrecurring
costs.
However, Adjusted EBITDA, Adjusted Operating Income and Adjusted
Net Income are not recognized measurements under GAAP and should
not be considered as an alternative to the most directly comparable
measures presented in accordance with GAAP. A reconciliation of
these non-GAAP measures to the most directly comparable GAAP
measures is included within this news release.
Conference Call Details
Landauer has scheduled its fourth quarter conference call for
investors over the Internet on Monday, December 14, 2015, at
5:00 p.m. Central Time (6:00 p.m. Eastern Time). To participate, callers
should dial 866-866-1542 (within the
United States and Canada),
or 707-294-1539 (international callers), passcode 1537908, about 10
minutes before the presentation. To listen to a webcast on the
Internet, please go to the Company's website at
http://www.landauer.com at least 15 minutes early to register,
download and install any necessary audio software. Investors may
access a replay of the call by dialing 855-859-2056 (within
the United States and Canada), or 404-537-3406 (international
callers), passcode 1537908, which will be available through
Wednesday, January 13, 2016. The
replay will also be available on Landauer's website for 30 days
following the call.
About Landauer
Landauer is a leading global provider of technical and
analytical services to determine occupational and environmental
radiation exposure, the leading domestic provider of outsourced
medical physics services, as well as a provider of high quality
medical accessories used in radiology, radiation therapy, and image
guided surgery procedures. For more than 50 years, the Company has
provided complete radiation dosimetry services to hospitals,
medical and dental offices, universities, national laboratories,
nuclear facilities and other industries in which radiation poses a
potential threat to employees. Landauer's services include the
manufacture of various types of radiation detection monitors, the
distribution and collection of the monitors to and from customers,
and the analysis and reporting of exposure findings. The Company
provides its dosimetry services to approximately 1.8 million
individuals globally. In addition, through its Medical Physics
segment, the Company provides therapeutic and imaging physics
services to the medical physics community. Through its Medical
Products segment, the Company provides medical consumable
accessories used in radiology, radiation therapy, and image guided
surgery procedures. For information about Landauer, please visit
their website at http://www.landauer.com.
Safe Harbor Statement
Some of the information shared here (including, in particular,
the section titled "Fiscal 2016 Outlook") constitutes
forward-looking statements that are based on assumptions and
involve certain risks and uncertainties. These include the
following, without limitation: assumptions, risks and uncertainties
associated with the Company's future performance; the Company's
development and introduction of new technologies in general; the
ability to protect and utilize the Company's intellectual property;
continued customer acceptance of the InLight technology; the
adaptability of optically stimulated luminescence (OSL) technology
to new platforms and formats; military and other government funding
for the purchase of certain of the Company's equipment and
services; the impact on sales and pricing of certain customer group
purchasing arrangements; changes in spending or reimbursement for
medical products or services; the costs associated with the
Company's research and business development efforts; the usefulness
of older technologies and related licenses and intellectual
property; the effectiveness of and costs associated with the
Company's IT platform enhancements; the anticipated results of
operations of the Company and its subsidiaries or joint ventures;
valuation of the Company's long-lived assets or business units
relative to future cash flows; changes in pricing of services and
products; changes in postal and delivery practices; the Company's
business plans; anticipated revenue and cost growth; the ability to
integrate the operations of acquired businesses and to realize the
expected benefits of acquisitions; the risks associated with
conducting business internationally; costs incurred for potential
acquisitions or similar transactions; other anticipated financial
events; the effects of changing economic and competitive
conditions, including instability in capital markets which could
impact availability of short and long-term financing; the timing
and extent of changes in interest rates; the level of borrowings;
foreign exchange rates; government regulations; accreditation
requirements; changes in the trading market that affect the costs
of obligations under the Company's benefit plans; and pending
accounting pronouncements. These assumptions may not materialize to
the extent assumed, and risks and uncertainties may cause actual
results to be different from what is anticipated today. These risks
and uncertainties also may result in changes to the Company's
business plans and prospects, and could create the need from time
to time to write down the value of assets or otherwise cause the
Company to incur unanticipated expenses. Additional information may
be obtained by reviewing the information set forth in Item 1A "Risk
Factors" and Item 7A "Quantitative and Qualitative Disclosures
about Market Risk" and information contained in the Company's
Annual Report on Form 10-K for the fiscal year ended
September 30, 2015 and other reports filed by the Company,
from time to time, with the Securities and Exchange Commission. The
Company does not undertake, and expressly disclaims, any duty to
update any forward-looking statement whether as a result of new
information, future events or changes in the Company's
expectations, except as required by law.
Financial Tables Follow
Landauer, Inc. and
Subsidiaries
|
Consolidated
Balance Sheets
|
|
|
|
|
|
|
|
(Dollars in
Thousands)
|
|
September
30,
2015
|
|
September 30,
2014
|
Assets
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
15,314
|
|
$
|
6,761
|
Receivables, net of
allowances of $1,556 in 2015 and $1,872 in 2014
|
|
|
32,412
|
|
|
34,707
|
Inventories
|
|
|
7,035
|
|
|
6,687
|
Prepaid expenses and
other current assets
|
|
|
6,992
|
|
|
6,178
|
Total current
assets
|
|
|
61,753
|
|
|
54,333
|
|
|
|
|
|
|
|
Property, plant and
equipment, net
|
|
|
46,367
|
|
|
46,757
|
Equity in joint
ventures
|
|
|
24,010
|
|
|
23,835
|
Goodwill
|
|
|
35,072
|
|
|
43,218
|
Intangible assets, net
of accumulated amortization of $38,662 in 2015 and $37,579
in 2014
|
|
|
13,052
|
|
|
14,077
|
Other
assets
|
|
|
28,490
|
|
|
34,366
|
Total
Assets
|
|
$
|
208,744
|
|
$
|
216,586
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
Total current
liabilities
|
|
$
|
38,493
|
|
$
|
44,728
|
|
|
|
|
|
|
|
Long-term
debt
|
|
|
133,385
|
|
|
133,585
|
Other non-current
liabilities
|
|
|
24,539
|
|
|
24,539
|
Total
liabilities
|
|
|
196,417
|
|
|
202,852
|
|
|
|
|
|
|
|
Stockholders'
Equity
|
|
|
|
|
|
|
Landauer, Inc.
stockholders' equity
|
|
|
11,195
|
|
|
12,254
|
Noncontrolling
interest
|
|
|
1,132
|
|
|
1,480
|
Total stockholders'
equity
|
|
|
12,327
|
|
|
13,734
|
Total Liabilities
and Stockholders' Equity
|
|
$
|
208,744
|
|
$
|
216,586
|
Landauer, Inc. and
Subsidiaries
|
Consolidated
Statements of Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended September
30,
|
|
|
Twelve Months
Ended September
30,
|
(Dollars in
Thousands, Except per Share)
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
Total
revenues
|
|
$
|
40,161
|
|
$
|
41,993
|
|
$
|
151,314
|
|
$
|
155,062
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost and
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
|
|
19,402
|
|
|
19,508
|
|
|
72,585
|
|
|
74,155
|
Selling, general and
administrative
|
|
|
12,901
|
|
|
13,109
|
|
|
53,989
|
|
|
54,904
|
Goodwill and other
intangible assets impairment charge
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
62,188
|
Acquisition,
reorganization and nonrecurring costs
|
|
|
1,041
|
|
|
2,024
|
|
|
1,041
|
|
|
3,802
|
Total costs and
expenses
|
|
|
33,344
|
|
|
34,641
|
|
|
127,615
|
|
|
195,049
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
(loss)
|
|
|
6,817
|
|
|
7,352
|
|
|
23,699
|
|
|
(39,987)
|
Equity in income of
joint ventures
|
|
|
503
|
|
|
867
|
|
|
2,307
|
|
|
2,939
|
Other expense,
net
|
|
|
(1,611)
|
|
|
(775)
|
|
|
(4,684)
|
|
|
(3,450)
|
Income (loss) before
taxes
|
|
|
5,709
|
|
|
7,444
|
|
|
21,322
|
|
|
(40,498)
|
Income tax expense
(benefit)
|
|
|
3,002
|
|
|
4,613
|
|
|
6,273
|
|
|
(15,800)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
(loss)
|
|
|
2,707
|
|
|
2,831
|
|
|
15,049
|
|
|
(24,698)
|
Less: Net income
attributed to noncontrolling interest
|
|
|
143
|
|
|
34
|
|
|
506
|
|
|
505
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
attributed to Landauer, Inc.
|
|
$
|
2,564
|
|
$
|
2,797
|
|
$
|
14,543
|
|
$
|
(25,203)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per
share attributed to Landauer, Inc. shareholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.27
|
|
$
|
0.31
|
|
$
|
1.52
|
|
$
|
(2.65)
|
Weighted average
basic shares outstanding
|
|
|
9,533
|
|
|
9,524
|
|
|
9,511
|
|
|
9,524
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
$
|
0.27
|
|
$
|
0.31
|
|
$
|
1.52
|
|
$
|
(2.65)
|
Weighted average
diluted shares outstanding
|
|
|
9,570
|
|
|
9,572
|
|
|
9,540
|
|
|
9,524
|
Landauer, Inc. and
Subsidiaries
|
Consolidated
Statements of Cash Flows
|
|
|
|
|
|
|
|
|
|
Twelve Months
Ended
September 30,
|
(Dollars in
Thousands)
|
|
2015
|
|
2014
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
Net income
(loss)
|
|
$
|
15,049
|
|
$
|
(24,698)
|
Adjustments to
reconcile net income (loss) to net cash provided by operating
activities:
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
12,312
|
|
|
13,915
|
Goodwill and other
intangible assets impairment charge
|
|
|
-
|
|
|
62,188
|
Equity in income of
joint ventures
|
|
|
(2,307)
|
|
|
(2,939)
|
Dividends from joint
ventures
|
|
|
1,144
|
|
|
1,340
|
Stock-based
compensation and related net tax benefits
|
|
|
1,583
|
|
|
2,074
|
Current and long-term
deferred taxes, net
|
|
|
238
|
|
|
(26,920)
|
Loss on sale, disposal
and abandonment of assets
|
|
|
181
|
|
|
208
|
Loss (gain) on
investments
|
|
|
176
|
|
|
(419)
|
Loss on disposition of
business
|
|
|
366
|
|
|
-
|
Changes in operating
assets and liabilities
|
|
|
(489)
|
|
|
11,936
|
Net cash provided
by operating activities
|
|
|
28,253
|
|
|
36,685
|
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
Acquisition of
property, plant and equipment
|
|
|
(7,974)
|
|
|
(4,161)
|
Proceeds from
disposition of business
|
|
|
6,958
|
|
|
-
|
Acquisition of joint
ventures and businesses, net of cash acquired
|
|
|
-
|
|
|
(1,800)
|
Other investing
activities, net
|
|
|
(1,262)
|
|
|
(1,255)
|
Net cash used in
investing activities
|
|
|
(2,278)
|
|
|
(7,216)
|
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
Long-term borrowings,
net
|
|
|
(200)
|
|
|
(9,260)
|
Dividends paid to
stockholders
|
|
|
(15,874)
|
|
|
(21,048)
|
Other financing
activities, net
|
|
|
(449)
|
|
|
(597)
|
Net cash used in
financing activities
|
|
|
(16,523)
|
|
|
(30,905)
|
|
|
|
|
|
|
|
Effects of foreign
currency translation
|
|
|
(899)
|
|
|
(475)
|
|
|
|
|
|
|
|
Net increase
(decrease) in cash and cash equivalents
|
|
|
8,553
|
|
|
(1,911)
|
Opening balance –
cash and cash equivalents
|
|
|
6,761
|
|
|
8,672
|
Ending balance – cash
and cash equivalents
|
|
$
|
15,314
|
|
$
|
6,761
|
Non-GAAP Financial
Measures
|
|
A reconciliation of
Adjusted EBITDA, Adjusted Operating Income and Adjusted Net Income
(i.e., non-GAAP financial measures) to the most directly comparable
GAAP measures is provided below:
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
September 30,
|
|
Twelve Months
Ended
September 30,
|
(Unaudited,
Dollars in Thousands)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
Adjusted
EBITDA
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
attributed to Landauer, Inc.
|
$
|
2,564
|
|
$
|
2,797
|
|
$
|
14,543
|
|
$
|
(25,203)
|
Add back:
|
|
|
|
|
|
|
|
|
|
|
|
Net financing
costs
|
|
1,258
|
|
|
919
|
|
|
3,910
|
|
|
3,426
|
Depreciation and
amortization
|
|
3,038
|
|
|
2,496
|
|
|
12,312
|
|
|
13,915
|
Provision for income
taxes
|
|
3,002
|
|
|
4,613
|
|
|
6,273
|
|
|
(15,800)
|
Earnings before
interest, taxes, depreciation
and amortization
(EBITDA)
|
$
|
9,862
|
|
$
|
10,825
|
|
$
|
37,038
|
|
$
|
(23,662)
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash stock based
compensation
|
|
160
|
|
|
995
|
|
|
1,583
|
|
|
2,074
|
Goodwill and other
intangible assets impairment charge
|
|
-
|
|
|
-
|
|
|
-
|
|
|
62,188
|
Acquisition,
reorganization and nonrecurring costs
|
|
1,041
|
|
|
2,024
|
|
|
1,041
|
|
|
3,802
|
Loss on disposition of
business
|
|
366
|
|
|
-
|
|
|
366
|
|
|
-
|
Transaction
expenses
|
|
528
|
|
|
-
|
|
|
528
|
|
|
-
|
Sub-total
adjustments
|
|
2,095
|
|
|
3,019
|
|
|
3,518
|
|
|
68,064
|
Adjusted
EBITDA
|
$
|
11,957
|
|
$
|
13,844
|
|
$
|
40,556
|
|
$
|
44,402
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended September
30,
|
|
Twelve Months
Ended September
30,
|
(Unaudited,
Dollars in Thousands)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
Adjusted Operating
Income
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
(loss)
|
$
|
6,817
|
|
$
|
7,352
|
|
$
|
23,699
|
|
$
|
(39,987)
|
Goodwill and other
intangible assets impairment charge
|
|
-
|
|
|
-
|
|
|
-
|
|
|
62,188
|
Acquisition,
reorganization and nonrecurring costs
|
|
1,041
|
|
|
2,024
|
|
|
1,041
|
|
|
3,802
|
Transaction
expenses
|
|
528
|
|
|
-
|
|
|
528
|
|
|
-
|
Adjusted Operating
Income
|
$
|
8,386
|
|
$
|
9,376
|
|
$
|
25,268
|
|
$
|
26,003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended September
30,
|
|
Twelve Months
Ended September
30,
|
(Unaudited,
Dollars in Thousands)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
Adjusted Net
Income
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
attributed to Landauer, Inc.
|
$
|
2,564
|
|
$
|
2,797
|
|
$
|
14,543
|
|
$
|
(25,203)
|
Sub-total
adjustments
|
|
2,095
|
|
|
3,019
|
|
|
3,518
|
|
|
68,064
|
Income taxes on
adjustments
|
|
(758)
|
|
|
(460)
|
|
|
(1,035)
|
|
|
(26,545)
|
Adjustments,
net
|
|
1,337
|
|
|
2,559
|
|
|
2,483
|
|
|
41,519
|
Adjusted Net
Income
|
$
|
3,901
|
|
$
|
5,356
|
|
$
|
17,026
|
|
$
|
16,316
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment
Information
|
|
The following tables
summarize financial information for each reportable segment for the
three and twelve months ended September 30:
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
September 30,
|
|
Twelve Months
Ended
September 30,
|
(Dollars in
Thousands)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
Revenues by
segment:
|
|
|
|
|
|
|
|
|
|
|
|
Radiation
Measurement
|
$
|
28,098
|
|
$
|
31,369
|
|
$
|
105,978
|
|
$
|
113,556
|
Medical
Physics
|
|
9,478
|
|
|
8,270
|
|
|
35,449
|
|
|
32,213
|
Medical
Products
|
|
2,585
|
|
|
2,354
|
|
|
9,887
|
|
|
9,293
|
Consolidated
revenues
|
$
|
40,161
|
|
$
|
41,993
|
|
$
|
151,314
|
|
$
|
155,062
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
September 30,
|
|
Twelve Months
Ended
September 30,
|
(Dollars in
Thousands)
|
2015
|
|
2014
|
|
2015
|
|
2014
|
Operating income
(loss) by segment:
|
|
|
|
|
|
|
|
|
|
|
|
Radiation
Measurement
|
$
|
9,239
|
|
$
|
12,136
|
|
$
|
35,641
|
|
$
|
38,231
|
Medical
Physics
|
|
1,044
|
|
|
360
|
|
|
3,126
|
|
|
1,827
|
Medical
Products
|
|
581
|
|
|
319
|
|
|
1,534
|
|
|
(62,572)
|
Corporate
|
|
(4,047)
|
|
|
(5,463)
|
|
|
(16,602)
|
|
|
(17,473)
|
Consolidated
operating income (loss)
|
$
|
6,817
|
|
$
|
7,352
|
|
$
|
23,699
|
|
$
|
(39,987)
|
For Further Information Contact:
Michael DeGraff
Sard Verbinnen &
Co
Phone: 312.895.4734
Email:
mdegraff@sardverb.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/landauer-inc-reports-fiscal-2015-fourth-quarter-and-full-year-results-300192550.html
SOURCE Landauer, Inc.